With the Brexit implementation period ending in four months, the UK government has launched a trade advisory group for international life sciences deal talks and given UK medtech a seat at the table.

As the UK looks to its future healthtech regulatory model after Brexit, the ABHI’s regulatory director Phil Brown suggests a system whereby the same product data can be used as the basis for entry not only to the EU, but also to global markets.

With Brexit moving ever closer, the UK medtech industry is trying to ensure that local manufacturers have a range of commercial options in overseas markets in the post-EU phase. The ABHI is playing a strong support role in this area, following up its recent international growth plan with a new US innovation hub, designed to offer outward-looking UK medtechs the tools to build positions in the world's largest market.